|Year : 2020 | Volume
| Issue : 6 | Page : 768-776
Clinacanthus nutans standardized fraction arrested SiHa cells at G1/S and induced apoptosis via upregulation of p53
Nik Aina Syazana Nik Zainuddin1, Hussin Muhammad2, Nik Fakhuruddin Nik Hassan3, Nor Hayati Othman4, Yusmazura Zakaria1
1 Biomedicine Programme, School of Health Sciences, Universiti Sains Malaysia (USM) Health Campus, 16150 Kota Bharu, Kelantan, Malaysia
2 Toxicology and Pharmacology Unit, Herbal Medicine Research Centre, Institute for Medical Research (IMR), 50588 Kuala Lumpur, Malaysia
3 Forensic Science Programme, School of Health Sciences, Universiti Sains Malaysia (USM) Health Campus, 16150 Kota Bharu, Kelantan, Malaysia
4 Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia (USM) Health Campus, 16150 Kota Bharu, Kelantan, Malaysia
|Date of Submission||05-Nov-2019|
|Date of Decision||16-Feb-2020|
|Date of Acceptance||26-Feb-2020|
|Date of Web Publication||05-Nov-2020|
Dr. Yusmazura Zakaria
Biomedicine Programme, School of Health Sciences, Universiti Sains Malaysia (USM) Health Campus, 16150 Kota Bharu, Kelantan.
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Introduction: Cervical cancer is a leading cause of death in women. Current cancer treatment comes with side effects. Clinacanthus nutans has been known traditionally to treat cancer. This study was aimed to characterize C. nutans standardized fraction (SF1) and to investigate its anticancer mechanism against SiHa cells. Materials and Methods: SF1 was produced by optimized methodology for bioassay-guided fractionation. Fourier transform infrared (FTIR) spectroscopy and liquid chromatography–mass spectrometry (LC-MS) were carried out to characterize the SF1. SF1 was screened for cytotoxicity activity toward HeLa, SiHa, and normal cells (NIH) cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The anticancer mechanism of SF1 was evaluated toward SiHa cells, which showed highest cytotoxicity toward SF1 treatment. The mechanism includes cell cycle progression and protein expression, which was detected using specific antibody-conjugated fluorescent dye, p53-FITC, by flow cytometry. Results: Major constituents of SF1 were alkaloids with amines as functional group. SF1 showed highest cytotoxic activity against SiHa (half-maximal inhibitory concentration [IC50] < 10 µg/mL) compared to HeLa cells. Cytoselectivity of SF1 was observed with no IC50 detected on normal NIH cells. On flow cytometry analysis, SF1 was able to induce apoptosis on SiHa cells by arresting cell cycle at G1/S and upregulation of p53 protein. Conclusion: SF1 showed anticancer activity by inducing apoptosis through arrested G1/S cell cycle checkpoint–mediated mitochondrial pathway.
Keywords: Apoptosis, cervical cancer, Clinacanthus nutans, cytotoxicity
|How to cite this article:|
Nik Zainuddin NA, Muhammad H, Nik Hassan NF, Othman NH, Zakaria Y. Clinacanthus nutans standardized fraction arrested SiHa cells at G1/S and induced apoptosis via upregulation of p53. J Pharm Bioall Sci 2020;12, Suppl S2:768-76
|How to cite this URL:|
Nik Zainuddin NA, Muhammad H, Nik Hassan NF, Othman NH, Zakaria Y. Clinacanthus nutans standardized fraction arrested SiHa cells at G1/S and induced apoptosis via upregulation of p53. J Pharm Bioall Sci [serial online] 2020 [cited 2022 Aug 9];12, Suppl S2:768-76. Available from: https://www.jpbsonline.org/text.asp?2020/12/6/768/299988
| Introduction|| |
Cancer has been known as one of the major health threats in this world. The World Health Organization reported that cervical cancer is the fourth most common cancer among women worldwide and the second most common cancer among women in Asia. Current treatment of cervical cancer that is commonly used, such as surgery, radiotherapy, and chemotherapy, failed to kill cancerous cells efficiently due to resistance and toxicity to healthy cells. Chemotherapy is unable to discriminate between healthy and cancerous cells; therefore, it becomes toxic for the body. A study showed up to 50% of patients with cancer were killed by the chemotherapy drugs, not the disease itself. Rise of prevalence in cancer has captured the attention of researchers who have been determined to find effective treatments. Many anticancer drugs have been developed using medicinal plants,, which is believed to improve survivorship in cancer. In this study, Clinacanthus nutans has been chosen based on the traditional claim from old folks in combating cervical cancer. Despite numerous identified studies related to antiproliferative activity of C. nutans and their responsible bioactive compounds are available, less information regarding its anticancer mechanism is reported. Hence, the aim of this study was to characterize the active anticancer compounds from C. nutans and to study its mechanism to evaluate the potential of C. nutans as an alternative potential treatment for cervical cancer.
| Materials and Methods|| |
Plant collection, extraction, and fractionation
The fresh leaves of C. nutans were collected from Pengkalan Chepa, Kelantan, Malaysia. The specimen was authenticated (no. PIIUM 0238-2) and deposited at Herbarium, Kulliyyah of Pharmacy, Universiti Islam Antarabangsa Malaysia (UIAM), Jalan Gombak, Selangor, Malaysia. The leaves were dried in an oven at 50°C overnight. The dried leaves were ground and sequentially extracted with hexane and chloroform, respectively. Standard fraction (SF1) was then produced by bioassay-guided fractionation, previously optimized by our colleagues.
Characterization of standardized fraction
Fourier transform infrared spectroscopy analysis
One gram of dried SF1 was scanned at wavelength ranging from 600 to 4000 nm, and the characteristic peaks and their functional groups were detected using Tensor-II-FTIR spectrometer, Bruker, Billerica, Massachusetts. The total run time was 15 min.
Liquid chromatography–mass spectrometry analysis
A 10 mg/mL of SF1 was injected using Agilent-1290-Infinity liquid chromatography (LC) system and separated using a C18 column (Agilent ZORBAX Eclipse XDB-C18, Narrow Bore 2.1 mm × 150 mm, 3.5 micron). The LC was coupled to an Agilent-6520 Accurate-Mass Q-TOF mass spectrometer with a dual Electrospray Ionisation source. The total run time was 30 min. The analysis was set to mass spectrometry (MS) mode with negative and positive polarity.
Cytotoxic activity of standardized fraction by MTT assay
MTT assay was performed toward two types of cervical cancer cells, HeLa and SiHa, and normal fibroblast cells, NIH cells. HeLa and NIH cells were maintained in Dulbecco Modified Eagle medium, whereas SiHa cells were maintained in Roselle’s Park Memorial Institute 1640 medium, supplemented with fetal bovine serum and penicillin–streptomycin. The cells were seeded at 5 × 104 cells/well in 96-well plates overnight. Ten milligram of SF1 was dissolved in Dimethyl sulfoxide (DMSO) and followed by a serial dilution ranged from 0.2 to 100 µg/mL. Cisplatin was used as a positive control and DMSO acted as a negative control. The treated plates were incubated for 72 h. The old medium was discarded and MTT solution was added. The plates were incubated for 4 h. MTT solution was removed and dissolved with DMSO. The plates were shaken for 30 min, and the absorbance at 570 nm was read on microplate reader. The percentage of cell viability was calculated as follows: (optical density (OD) treated)/(OD negative control) × 100%. Dose response curves were constructed to obtain half-maximal inhibitory concentration (IC50) values.
Sample preparation for flow cytometry analysis
The cells for each flask were seeded at 5 × 104 cells/mL overnight. The next day, cells were treated with IC50 of SF1 and IC50 of cisplatin for 24, 48, and 72 h. Untreated cells were used as negative control. The SF1-treated, cisplatin-treated, and untreated cells were harvested by centrifugation.
Cell cycle analysis of cell-treated standardized fraction by flow cytometry
After centrifugation, all the cells were fixed in cold 70% ethanol for 1 h. Pellet of cell was then resuspended with 1 mL of 1% Triton X-100 in phosphate-buffered saline (PBS) and 100 µL of 1 mg/mL RNase A. The mixture was kept at 37°C for half an hour. Cells were stained with 10 µg/mL propidium iodide solution in staining buffer. Incubation was allowed for 30 min and tubes were kept in ice. Before flow cytometric analysis, 300 µL of staining buffer was added and analyzed.
Detection of apoptotic protein, p53, in cell-treated standardized fraction by flow cytometry
After centrifugation, all the cells were fixed in ice cold 70% ethanol for 1 h. The cell pellet was washed twice with ×1 PBS and resuspended in a blocking buffer (2% bovine serum albumin) for 10 min. Again, washing step was carried out. Cell pellet was resuspended in PBS to a concentration of 1 × 107 cells/mL. Then, 100 µL of cell suspension (1 × 106 cells/mL) was transferred into flow cytometry tubes, and 20 µL of p-53/Fluorescein isothiocyanate-conjugated antibody was added. The tubes were mixed and left for 30 min in the dark at room temperature. The cells were washed with ×1 PBS, resuspended in ×1 PBS, and proceeded with flow cytometric analysis.
| Results|| |
Fourier transform infrared spectroscopy analysis of standardized fraction
Amines have been detected as the most abundant functional groups present in SF1, followed by alkanes, alkenes, esters, and aromatics [Figure 1]. The identified amines include aromatics amine and aliphatic amines [Table 1].
|Figure 1: Fourier transform infrared spectroscopy spectrum of standardized fraction|
Click here to view
|Table 1: Peak value of Fourier transform infrared spectroscopy and its different functional group in standardized fraction|
Click here to view
Liquid chromatography–mass spectrometry analysis of standardized fraction
Mass spectrum identification was matched with METLIN database and composition that possessed higher peaks in the chromatogram with more 95 DB, database score is referred as the closeness match of the compound with the database [Table 2] and [Table 3].
|Table 2: List of standardized fraction major constituents detected in positive mode|
Click here to view
|Table 3: List of standardized fraction major constituents detected in negative mode|
Click here to view
The major known constituents from positive polarity [Table 2] belong to alkaloids, a class of nitrogenous organic compound. They are methysergide, calycanthine, eburnamonine, and dextromethorphan. There was one unknown compound, C33H37N5OS2 that does not match with METLIN database [Figure 2]. As compared to negative polarity [Figure 3], there was one known constituent identified as α-9(10)-EpODE, fatty acids, and two unknown constituents, C21H38N4O4S and C16H26O3S [Table 3]. Molecular structure of major known compounds from positive polarity had a ring structure, whereas major known compounds from negative polarity displayed long chain structure [Figure 4].
|Figure 4: The structure of major known compounds detected from positive and negative polarity that present in standardized fraction|
Click here to view
Cytotoxicity of standardized fraction
SF1 showed potent inhibition toward SiHa cells with lowest IC50 values of 9.98 ± 1.24 µg/mL as compared to HeLa cells [Figure 5]. Cisplatin showed high cytotoxic activity on all tested cell lines; 2.76 ± 1.06 µg/mL on NIH cells, 2.95 ± 1.20 µg/mL on HeLa, and 2.29 ± 1.16 µg/mL on SiHa cells. No IC50 value was detected on normal cell, NIH, which showed no inhibition effect on the treatment with SF1. This indicated that the cytotoxicity effect of SF1 was selective toward SiHa cells. SiHa cells were also more susceptible to the SF1 treatment than HeLa cells. Hence, for subsequent experiments, SiHa cells were selected to determine the anticancer mechanism of SF1.
|Figure 5: Dose response curves (A) standardized fraction and (B) cisplatin toward HeLa, SiHa, and NIH cells. Each point showed the percentage of viable cells compared to negative control, DMSO. Each point represented as mean ± SD, n = 3|
Click here to view
Cell cycle arrest by standardized fraction
[Figure 6] showed DNA content profile of SiHa cells in all tested groups for 24, 48 and 72 hours. The DNA content is reflex to the presence of DNA in the cell population. The percentage of DNA content at G2/M remained high throughout all treatment durations, which indicated that the mitosis occurred as a common process in untreated SiHa cells. In SF1-treated SiHa cells [Figure 7]B, the pattern of cell cycle was altered at the end of 72 h of treatment duration. The DNA content in G0/G1 phase at 24 h was 46.59% ± 1.05%, and it reduced to 31.94% ± 0.89% at the S phase. The cell population was significantly reduced (P < 0.01) to 21.46% ± 0.62% in the G2/M phase. This cell cycle trend was similar throughout 48 and 72 h of SF1-treated SiHa cells, with 42.35% ± 1.44% and 40.56% ± 1.05% cells were arrested at G1/G0 phase, respectively. During S phase, 35.60% ± 3.31% at 48 h and 46.14% ± 2.46% at 72 h were recorded. At the end of 72 hr, there was 13.29% ± 2.38% of SF1-treated SiHa cells entered G2/M phase (P < 0.01), which indicated that less percentage of cell proliferation and could not undergo mitosis phase. Similarly in cisplatin-treated SiHa cells [Figure 7]C, most of the cell population was accumulated at G1/S with 54.95% ± 3.33% and only 10.42% ± 1.29% was detected at G2/M phase.
|Figure 6: DNA content of SiHa cells in untreated SiHa cells (UT), standardized fraction-treated SiHa cells (SF1), and cisplatin-treated SiHa cells (CP) for 24, 48, and 72 h. Similar plots were observed in three independent experiments (n = 3). Indicator: Green = G1/S, Blue = S, Red = G2/M|
Click here to view
|Figure 7: Graph summarized the percentage of DNA content of SiHa cells in each cell cycle phase for (A) untreated SiHa cells, (B) standardized fraction (SF1)-treated SiHa cells, and (C) cisplatin-treated SiHa cells. Each point represented mean ± SD of three independent experiments, and **P < 0.01 and *P < 0.05 were taken as significantly different with treatment duration|
Click here to view
Quantification of apoptotic protein
[Figure 8] showed profile of p53 proteins expression of SiHa cells in all tested groups for 24, 48 and 72 hours. This study indicated that SF1 successfully caused highest accumulation of p53 protein up to 92.33% ± 3.56% at 72 h (P < 0.001) compared to 53.17% ± 3.19% at 48 h, and 19.50% ± 0.92% at 24 h of treatment in SiHa cells [Figure 9]. On the contrary, in untreated SiHa cells, the percentage of p53 remained at the lowest with 0.46% ± 0.45% at 24 h, 1.43% ± 0.35% at 48 h, and 3.90% ± 0.53% at 72 h. The level of p53 protein in cisplatin-treated SiHa cells was dramatically increased from 35.60% ± 4.50% at 24 h to 95.97% ± 2.30% at 48 h and 98.53% ± 0.49% at the end of 72 h.
|Figure 8: Histogram profile of p53 proteins expression detected by flow cytometry analysis in untreated SiHa cells (UT), standardized fraction-treated SiHa cells (SF1), and cisplatin-treated SiHa cells (CP) for 24, 48, and 72 h. Similar profile was observed in three independent experiments (n = 3)|
Click here to view
|Figure 9: Graph summarized the expression levels of p53 for untreated SiHa cells, standardized fraction-treated SiHa cells, and cisplatin-treated SiHa cells. The value of bars represented mean ± SD of three independent experiments, and ***P < 0.001 was taken as a significant difference with the treatment durations|
Click here to view
| Discussion|| |
Bioassay-guided fractionation was carried out to produce SF1 due to the main goal to characterize the compounds present in C. nutans that are responsible as anticancer agent., In this study, the bioassay-guided fractionation involved various extraction techniques including soaking, rotary evaporation, and column chromatography. The IR spectroscopic analysis was carried out to determine the chemical functional groups, and the MS analysis was carried out to determine the selectively accurate mass of compounds present in the SF1. A research study identified a polysaccharide–peptide complex from C. nutans leaves, which showed inhibition for gastric cells. On the basis of the results of this study, major phytochemical class of SF1 was identified as alkaloids with functional group, amines. Alkaloids are the class of naturally occurring amines, which mostly contain organic nitrogen containing bases., Some of the alkaloids have already been successfully developed into chemotherapeutic drugs, such as vinblastine, taxol, and vincristine. They are known for having potent anticancer activity against various cancers., A few notable phytochemical compounds of C. nutans that relate to anticancer property, such as 1,2-benzenedicarboxylic acid monoester, were the major chemical constituents from chloroform leaf extract, which were capable to inhibit the growth of HeLa cells. High-performance LC-MS-identified flavonoids were presented in ethanol extract of C. nutans leaves, and they potentially inhibited hepatoma in mice. Hence, based on the findings, it was found that the main source of anticancer activity of SF1 was produced by secondary metabolites, alkaloids.
To assess and characterize the potentially toxic and selective effects of SF1, cell viability assay was performed. Any changes in the number of viable cells are linearly related to mitochondrial activity where activity of cells on treatment with any drugs can be measured by MTT assay. From here, IC50 values were obtained as half-maximal inhibitory concentration (IC50) in a 100% population. The result showed that no IC50 value was detected on cell proliferation of normal cells, NIH-treated with SF1. The IC50 value for SF1 may be higher than the highest concentration (100 µg/mL) used in this experiment. The IC50 value more than 99 µg/mL on the proliferation of normal cells indicated no inhibition effects. Similar findings also revealed that ethyl acetate and methanol roots extract of C. nutans showed little inhibition on NIH cells, which indicated no harmful effect on the healthy cells. On the contrary, ethyl acetate and ethanol extracts of C. nutans showed lower IC50 values against NIH cells with some effects on the proliferation of normal cells. Cisplatin showed strong cytotoxic activity on all tested cell lines including normal cells, NIH. This action provides an evidence that treatment with cisplatin has a general and unspecified target., SF1 showed potent IC50 value toward SiHa cells than that toward HeLa cells. The different cytotoxic effect on HeLa and SiHa cells might be due to the different tumorigenicity among them. HeLa cells contain more than 50 copies of human papillomavirus type 18 (HPV-18), whereas SiHa cells contain 1–2 copies of HPV-16. To compare with other related studies, dichloromethane fraction of C. nutans showed cytotoxicity against HeLa with IC50 value of 70 μg/mL after 48 h of treatment. The growth of HeLa cells was inhibited when treated with chloroform extract and active fraction of C. nutans., SF1 showed a better inhibition with highly toxic towards SiHa cells and nontoxic to normal cells. The ability of SF1 to selectively kill SiHa cells could lead to cell-specific drugs without the side effects. Therefore, further study on the SF1 mechanism toward the inhibition of SiHa cells was proceeded.
The regulation of cell cycle is responsible to either inhibit or induce cell growth. The relative DNA contents in all tested groups were analyzed using flow cytometer and represented as three different stages within the interphase of cell cycle known as G0/G1, S, and G2/M phases. On the basis of the findings, the distribution of SiHa cells in G0/G1 and S phase was notably decreased following treatment duration in SF1-treated group as compared to that in the untreated group. This indicated that SF1 significantly triggered the DNA damage within 72 h and caused cell cycle to stop. Thus, the current finding recommended that SF1 inhibited the proliferation of SiHa cells by promoting the cell cycle arrest at G1/S checkpoint. These data were similar with the previous findings reported on HeLa and A549 cells arrested cell cycle at G1/S phase on 72 h treatment with an active fraction of C. nutans., However, dichloromethane extract of C. nutans arrested HeLa cell at S phase after 48 h of treatment.
Many previous studies reported that cell cycle arrest induced apoptosis by the increased levels of p53., In this study, the main focus was on intrinsic pathway. The activation of this pathway is mainly regulated by p53 protein. It is known as the guardian of genome and is the most frequently mutated gene in almost all types of cancers. Various apoptotic signals are activated by DNA damage, cytotoxic agents, and p53 activation. On the basis of the results, the level of p53 increased gradually at 24–72 h of treatment with SF1. The percentage of p53 on treatment with SF1 was similar with cisplatin-treated SiHa cells at the end of 72 h incubation. This indicated that the SF1-activated p53 resulted from DNA damage. p53 is able to regulate the expression of proteins that plays the major roles in growth arrest and apoptosis. Therefore, SF1 induced cell death in SiHa cells via apoptosis-dependent p53-mediated pathway. Several previous studies showed that apoptosis was induced by the elevation of p53 via mitochondrial apoptotic pathway in human cervical cancer cells., The p53 plays a critical role in the G1/S checkpoint of cell cycle, and this checkpoint is recognized as being entirely p53 dependent.
| Conclusion|| |
These findings are pivotal as this is the first report on anticancer effect of standardized fraction extracted from C. nutans, SF1, against cervical cancer cell, SiHa. SF1 was successfully characterized as alkaloids with amines as functional group. SF1 has been found to have cytoselective anticancer effects toward SiHa by damaging the DNA, and it leads to p53 activation at G1/S checkpoint, which results in cell cycle arrest and apoptosis. Further investigation including elucidation of in vivo antitumor suppression of SF1 and the underlying mechanism are currently being carrying out.
The authors thank the Universiti Sains Malaysia (USM) for funding this work under Research University Incentives (RUI 1001/PPSK/812165) grant. The authors also thank School of Health Sciences and the School of Medical Sciences, Universiti Sains Malaysia (USM) for providing the research facilities.
Financial support and sponsorship
This work was supported by Research University Incentives (RUI 1001/PPSK/812165) grant, Universiti Sains Malaysia (USM), Malaysia.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, et al
; ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Available from: https://www.hpvcentre.net/datastatistics.php. Cited 2019 September 2. [Last accessed on 2019 sept 1].
Wallington M, Saxon EB, Bomb M, Smittenaar R, Wickenden M, McPhail S, et al
. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol 2016;17:1203-16.
Habli Z, Toumieh G, Faffat M, Rahal ON, Gali-Muhtasib H Emerging cytotoxic alkaloids in the battle against cancer: overview of molecular mechanism. Molecules 2017;22:E250.
He SH, Liu HG, Zhou YF, Yue QF Liquiritin (LT) exhibits suppressive effects against the growth of human cervical cancer cells through activating Caspase-3 in vitro
and xenograft mice in vivo
. Biomed Pharmacother 2017;92:215-28.
Ghasemzadeh A, Nasiri A, Jaafar HZ, Baghdadi A, Ahmad I Changes in phytochemical synthesis, chalcone synthase activity and pharmaceutical qualities of sabah snake grass (Clinacanthus nutans
L.) in relation to plant age. Molecules 2014;19: 17632-48.
Sakdarat S, Shuyprom A, Pientong C, Ekalaksananan T, Thongchai S Bioactive constituents from the leaves of Clinacanthus nutans
Lindau. Bioorg Med Chem 2009;17:1857-60.
Roslan SNFM, Zakaria Y, Abdullah H Cytotoxicity of Clinacanthus nutans and mechanism of action of its active fraction towards human cervical cancer cell line, HeLa. J Sains Kesihatan Malaysia 2018;16:39-50.
Huang D, Li Y, Cui F, Chen J, Sun J Purification and characterization of a novel polysaccharide–peptide complex from Clinacanthus nutans
Lindau leaves. Carbohydr Polym 2016;137:701-8.
Liu J, He Y, Zhang D, Cai Y, Zhang C, Zhang P, et al
. In vitro
anticancer effects of two novel phenanthroindolizidine alkaloid compounds on human colon and liver cancer cells. Mol Med Rep 2017;16:2595-603.
Mohan K, Jeyachandran R, Deepa. Alkaloids as anticancer agents. Ann Phytomed 2012;1:46-53.
Yong YK, Tan JJ, Teoh SS, Mah SH, Ee GCL, Chiong HS, et al
. Clinacanthus nutans extracts are antioxidant with antiproliferative effect on cultured human cancer cell lines. Evid Based Complement Alternat Med 2013;462751:1-8.
Huang D, Guo W, Gao J, Chen J, Olatunji JO Clinacanthus nutans
(Burm. f.) Lindau ethanol extract inhibits hepatoma in mice through upregulation of the immune response. Molecules 2015;20:17405-28.
Riss TL, Moravec AR, Niles AL, Duellman S, Benink HA, Worzella TJ, et al
. Cell viability assays: assay guidance manual 2013. Availablefrom: https://www.ncbi.nlm.nih.gov/books/NBK144065/. Cited 2019 Oct 3. [Last accessed on 2019 Oct 2].
Pei YN, Soi MC, Chew HN, Rhun YK, Yee LT, Liew PP, et al
. Clinacanthus nutans hexane extracts induce apoptosis through a caspase-dependent pathway in human cancer cell lines. Asian Pac J Cancer Prev 2017;18:917-26.
Zazali K, Abdullah H, Jamil N Methanol extract of Oroxylum indicum
leaves induces G1/S cell cycle arrest in HeLa cells via p53-mediated pathway. Int J Med Plant Res 2017;2: 225-37.
Teoh PL, Cheng AY, Liau M, Lem FF, Kaling GP, Chua FN, et al
. Chemical composition and cytotoxic properties of Clinacanthus nutans
root extracts. Pharm Biol 2017;55:394-401.
Sulaiman ISC, Basri M, Chan KW, Ashari SE, Masoumi HRF, Ismail M In vitro
antioxidant, cytotoxic and phytochemical studies of Clinacanthus nutans Lindau leaf extracts. Afr J Pharm Pharmacol 2015;934:861-74.
Zhen S, Lu JJ, Wang LJ, Sun XM, Zhang JQ, Li X, et al
. In vitro
and in vivo
synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR/cas9 on cervical cancer cell line. Transl Oncol 2016;9:498-504.
Haron NH, Md Toha Z, Abas R, Hamdan MR, Azman N, Khairuddean M, et al
. In vitro
cytotoxic activity of Clinacanthus nutans
leaf extracts against HeLa cells. Asian Pac J Cancer Prev 2019;20:601-9.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9]
[Table 1], [Table 2], [Table 3]